Pablo Luis Ortiz Romero
Hospital Universitario 12 De Octubre,Madrid, Spain · Hospital Universitario 12 de Octubre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pablo Luis Ortiz Romero as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04128072 · Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaEuropean Organisation for Research and Treatment of Cancer - EORTC · recruiting · Stage IB-IIB Cutaneous T-Cell Lymphoma · principal investigator
- Ph3NCT01386398 · Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaEuropean Organisation for Research and Treatment of Cancer - EORTC · withdrawn · Lymphoma · unknown
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:29 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- 21 citationsRCR 0.9